Mainz Biomed Gains Swissmedic Approval for ColoAlert®

Mainz Biomed N.V., a US and Germany-based molecular genetics diagnostic company, has announced Swissmedic's approval for ColoAlert®, its non-invasive colorectal cancer screening test. This marks a significant advancement for the company in the Swiss market.

ColoAlert® targets individuals between 50 and 74, a group comprising nearly one-third of Switzerland’s population. Despite existing CRC screening options, participation rates are low, highlighting the potential impact of ColoAlert® to enhance preventive healthcare efforts.

The approval follows a partnership with a Swiss laboratory, facilitating ColoAlert®'s market introduction in Switzerland. This aligns with Mainz Biomed’s strategy to extend access to their early detection solutions, aiming to reduce colorectal cancer mortality rates.

ColoAlert® employs advanced diagnostics to identify tumor DNA in stool samples, enhancing CRC detection accuracy. Mainz Biomed plans to further expand ColoAlert® through partnerships with regional healthcare providers across Europe.